What Is a Pharmacy Benefit Manager (PBM) and Why Does It Matter?

Three companies control nearly 80% of the prescription drug market. Understanding how PBMs work explains why your medications cost what they do.

If you've ever wondered why a generic drug that costs a manufacturer $0.05 per pill ends up costing you $30 at the pharmacy, the answer usually involves three letters: PBM.

A Pharmacy Benefit Manager is a middleman company that sits between drug manufacturers, insurance companies, pharmacies, and patients. Three PBMs control roughly 80% of the U.S. prescription drug market. Understanding what they do — and how they make money — explains a lot about why American drug prices are what they are.

What PBMs Actually Do

PBMs were originally created to process prescription claims — essentially handling the paperwork between your pharmacy and your insurance company. Over time, they took on more responsibilities and more power. Today, PBMs negotiate drug prices with manufacturers on behalf of insurers and employers, decide which drugs are covered on insurance formularies (the list of approved medications), set the reimbursement rates that pharmacies receive for filling prescriptions, and operate their own mail-order pharmacies.

In theory, PBMs save money by using their massive purchasing power to negotiate lower drug prices. In practice, the system has become far more complicated — and far less transparent — than that.

The Transparency Problem

PBMs negotiate rebates from drug manufacturers. A manufacturer might set a list price of $100 for a drug, then pay the PBM a $30 rebate to keep the drug on the formulary. In theory, that rebate should flow back to the insurer or employer who hired the PBM, lowering costs for patients. In practice, PBMs have been criticized for keeping a portion of rebates, for "spread pricing" (paying the pharmacy less than they charge the insurer and pocketing the difference), and for steering patients toward higher-cost drugs that generate larger rebates.

Because PBM contracts are typically confidential, it's been difficult for employers, insurers, and patients to see exactly how much money flows through the system and where it goes. This opacity has drawn scrutiny from Congress, the FTC, and state regulators.

The Three Major PBMs

The market is dominated by three companies, each owned by a larger healthcare conglomerate: CVS Caremark (owned by CVS Health, which also owns CVS pharmacies and Aetna insurance), Express Scripts (owned by Cigna), and OptumRx (owned by UnitedHealth Group, which also owns UnitedHealthcare). This vertical integration — where the same company owns the insurer, the PBM, and the pharmacy — creates potential conflicts of interest that regulators are increasingly examining.

What's Changing

Growing public pressure has driven some reforms. Some PBMs have begun moving to "pass-through" pricing models where rebates flow directly to the plan sponsor. Legislation at federal and state levels is targeting rebate transparency, spread pricing, and PBM-pharmacy conflicts of interest. And alternative models — like Cost Plus Drugs, which bypasses PBMs entirely — are demonstrating that transparent pricing is viable at scale.

For individual patients, the practical takeaway is this: the price your pharmacy charges isn't necessarily the "real" price of the drug. Tools like RxGator help you see past the PBM markup by comparing the actual cash prices, discount card rates, government benchmarks, and direct-to-consumer options — so you can find the price closest to what the drug actually costs.